Niki BioSolutions NIKI

Aptorum Group Limited is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology and infectious diseases. The company conducts its operations primarily through research and development activities, having ceased therapeutic services and now concentrating all efforts on advancing its lead drug candidates. Its work spans preclinical and clinical stages, with an emphasis on novel and repurposed therapeutics across various disease areas.

Aptorum Group Limited generates revenue through the potential future commercialization of its drug candidates, including milestone payments, royalties, and sales of approved products. Currently, as a preclinical and clinical stage company, it does not generate significant product revenue and relies on funding mechanisms such as equity offerings, convertible notes, and private placements to support its research and development activities. The company's financial strategy centers on securing capital to advance its pipeline toward regulatory approval and eventual marketization.

As of December 31, 2025, the company operates in a single segment dedicated to research and development of therapeutic and diagnostic innovations.

• Research and Development: This segment encompasses the discovery and development of drug candidates such as ALS-4 and SACT-1, along with associated diagnostic technologies. The company advances these candidates through preclinical studies, clinical trials, and regulatory engagement with agencies such as the U. S. FDA and Health Canada. It leverages proprietary platforms like the Smart-ACT® drug discovery system and collaborates with academic institutions and contract research organizations to support development.

Aptorum Group Limited operates in a highly competitive biopharmaceutical industry characterized by rapid innovation and intense competition from larger pharmaceutical firms, biotechnology companies, and academic research institutions. Its competitive advantages stem from its focus on orphan indications, repurposed drug strategies, and proprietary technologies that aim to reduce development risk and time. The company seeks to differentiate itself through targeted therapies addressing unmet medical needs, particularly in oncology and infectious diseases, where barriers to entry are high but potential rewards are substantial.

The company's primary customers are expected to be healthcare providers, including hospitals and clinics specializing in oncology and infectious disease treatment, as well as patients suffering from conditions such as neuroblastoma and antibiotic-resistant bacterial infections. While specific customer names are not disclosed due to the pre-revenue stage of its products, the company anticipates serving specialized medical institutions and patient populations in North America, Europe, and other key markets upon successful commercialization of its candidates.